Načítá se...
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer
Histologic transformation to small cell neuroendocrine prostate cancer occurs in a subset of patients with advanced prostate cancer as a mechanism of treatment resistance. Rovalpituzumab tesirine (SC16LD6.5) is an antibody-drug conjugate that targets delta-like protein 3 (DLL3) and was initially dev...
Uloženo v:
| Vydáno v: | Sci Transl Med |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6525633/ https://ncbi.nlm.nih.gov/pubmed/30894499 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aav0891 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|